Paxlovid in Ireland | Blocking a viral protease and slowing drug breakdown
Blocking a viral protease and slowing drug breakdown.
Health / The Compound journalPhoto: Intellec7 · 2022 · CC BY-SA 4.0 · framed · Illustrative image.
At a glance
Paxlovid combines nirmatrelvir and ritonavir for eligible people with COVID-19. Eligibility, timing and interaction checks depend on the current Irish pathway and the person’s medicines and medical history. HSE guide
The Science Behind the Drug
Blocking a viral protease and slowing drug breakdown
SARS-CoV-2 makes long protein chains that its main protease cuts into working proteins. Nirmatrelvir inhibits that protease. Ritonavir inhibits CYP3A and slows breakdown of nirmatrelvir, maintaining exposure. It also changes exposure to other drugs processed through that pathway, which is why the interaction check is central. EMA source
What the evidence measures
Antiviral trials often measure hospitalisation or death in people at higher risk. Absolute benefit depends on baseline risk, population and when treatment starts. Results should be read in the context of the population studied.
Have two lists ready for a treatment call
| What to check | Why it matters |
|---|---|
| Illness | symptom onset date and relevant medical history |
| Medicines | all regular and recently used prescriptions, products and supplements |
Why do clinicians ask about recently stopped medicines?
Some medicines can continue affecting drug metabolism after the last dose. Provide names and dates so the team can make the interaction and eligibility assessment.
When to ask for help or a medication review
Ask a clinician or pharmacist to screen the whole medicine list and check kidney function. Do not stop co-medications or decide eligibility on the basis of a web page. HSE patient guidance
Why kidney function and the medicine list answer different questions
Kidney function affects how much nirmatrelvir can remain in the body, and can change the prescriber’s approach. The full medicine list answers a separate question: ritonavir affects breakdown of many drugs and can cause important interactions. List supplements and occasional medicines as well as prescriptions. For recently stopped medicines, include the last day taken because some effects on drug metabolism can last beyond the last dose. EMA Paxlovid information
What makes the reported treatment benefit relevant?
A study in people at higher risk of severe COVID can show a reduction in hospitalisation or death under particular conditions. The absolute benefit depends on the risk in the group studied, the period of follow-up, and timing after symptom onset. Ask the clinician how the evidence fits your risk and the current Irish pathway. EMA Paxlovid information · HSE Paxlovid guidance
Write down when symptoms first appeared and have the packs to hand for the prescribing discussion. The clinician can decide if a medicine can be paused, adjusted or requires a different antiviral plan. Do not make those changes from an online interaction list. HSE Paxlovid guidance
A medication reconciliation example
A person may say “I take a cholesterol tablet and something for sleep.” Each description could cover several medicines with very different interactions. Have the packs ready and give the exact name, strength, usual timing and last dose. Include an occasional treatment, a herbal product or a prescription recently stopped. The prescriber can then use a current interaction resource for the actual list. EMA Paxlovid information
Related guides
Statins · How to find the Irish patient leaflet
Close-up of Paxlovid tablets. Image licence.


